Skip to main content
Premium Trial:

Request an Annual Quote

DxS Teams with AstraZeneca on Iressa Companion Dx

NEW YORK (GenomeWeb News) – DxS today said that it has entered into a partnership with AstraZeneca to potentially market a companion diagnostic for the drug firm's gefitinib (Iressa) treatment for non small cell lung cancer.

DxS said that its TheraScreen EGFR29 Mutation Kit will be used to test the mutation status of patients' EGFR oncogene to identify their eligibility for treatment with Iressa. Manchester, UK-based DxS has already CE-marked the TheraScreen EGFR29 Mutation Kit.

The alliance follows European Union marketing authorization of Iressa for treating adults with locally advanced or metastatic NSCLC with activating mutations of EGFR-TK across all lines of therapy.

Iressa inhibits the tyrosine kinase enzyme in the Epidermal Growth Factor Receptor (EGFR), thus blocking the transmission of signals involved in the growth and spread of tumors, said DxS. In approximately 10 percent to 15 percent of NSCLC cases in Caucasians, a mutation in the EGFR pathway causes tumors to be particularly susceptible to treatment with IRESSA, which makes the use of a companion diagnostic to identify those most suitable for treatment extremely important, the molecular diagnostics firm said.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.